Can a common breast cancer drug work equally well in underrepresented groups?

NCT ID NCT07760714

Completed Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Aug 12, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study looks back at medical records to see how ribociclib, a CDK4/6 inhibitor used for hormone receptor-positive, HER2-negative metastatic breast cancer, is prescribed and tolerated in older adults (65 and over) and Black/African American patients. These groups are often underrepresented in clinical trials. The goal is to understand real-world treatment patterns, side effects, and effectiveness in these populations, using data from a large U.S. oncology database.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ribociclib (a CDK4/6 inhibitor)
What this could lead to: If successful, this could reveal whether ribociclib works as well in older and Black patients as in other groups, helping tailor breast cancer care.
What could go wrong: This is a retrospective, observational study, so it cannot prove cause and effect. Results may be limited by data quality and may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Novartis

East Hanover, New Jersey, 07936, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.